On April 17, 2025 Interius BioTherapeutics, a clinical-stage company engineering targeted, programmable vectors for the precision delivery of genetic medicines, reported that it will present at several upcoming scientific meetings (Press release, Interius BioTherapeutics, APR 17, 2025, View Source [SID1234651973]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Cellicon Valley ’25: The Future of Cell and Gene Therapies
Philadelphia, PA
April 30 – May 2, 2025
Plenary Session: Are In Vivo Cell Therapies the Key to the Future of Medicine?
Presentation Title: Cell-specific in vivo gene delivery: A pipeline dream no longer
Presenter: Philip Johnson, M.D., Chief Executive Officer, Interius BioTherapeutics
Presentation Date and Time: Thursday, May 1, at 3:50 pm EDT
International Society for Cell and Gene Therapy (ISCT) 2025 Annual Meeting
New Orleans, LA
May 7 – 10, 2025
Scientific Session: In Vivo Cell Engineering: Breaking Through the Manufacturing Bottleneck
Presentation Title: INVISE: A first-in-human Phase 1 clinical trial evaluating the safety of INT2104 for in vivo generation of CAR T and CAR NK cells in adults with relapsed/refractory B cell malignancies
Presenter: Dr. David Bishop, Haematologist, Westmead Hospital, Sydney, Australia
Presentation Date and Time: Friday, May 9, at 9:15 am CT
American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 28th Annual Meeting
New Orleans, LA
May 13 – 17, 2025
Scientific Symposium: The Coalition of International Gene Therapy Societies Showcases: Moving from ex vivo Cell Therapies to in vivo
Presentation Title: Investigational in vivo CAR-T therapy designed to treat B-cell malignancies
Presenter: Philip Johnson, M.D., Chief Executive Officer, Interius BioTherapeutics
Presentation Date and Time: Thursday, May 15, from 3:45 – 5:30 pm CT
Location: Room 265-268